Primary and secondary safety endpoints from IMPACT II

American Journal of Cardiology

Volumn 80, Issue 4 A, 1997, Pages 29B-33B

  Kleiman, Neal S ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CYCLOPEPTIDE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HEPTAPEPTIDE; PLACEBO; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ATHERECTOMY; BACKACHE; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; EXCIMER LASER; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0030845665     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00574-2     Document Type: Conference Paper

References (17)

1. Knight DM, Wagner C, Jordan R, McAleer MF, DeRita R, Fass DN, Coller BS, Weisman HF, Ghrayeb J. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol. 32:1995;1271-1281.
2. Coller BS. Blockade of platelet GP IIb/IIIa receptors as an antithrombotic strategy. Circulation. 92:1995;2373-2380.
3. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
4. Arky R. med consult. Physicians' Desk Reference. 50th ed. 1996;1471-1474 Medical Economics Co, Montvale, NJ.
5. Berkowitz SD, Sane DC, Shavender JH, Sigmon KN, Topol EJ, Califf RM. Analysis of the occurrence and clinical significance of thrombocytopenia with c7E3 (abciximab) in the EPIC trial. (Abstr.). J Am Coll Cardiol. 27:1996;82A.
6. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 349:1997;1429-1435.
7. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
8. Charo IF, Scarborough RM, du Mée CP, Wolf D, Phillips DR, Swift RL. Pharmacodynamics of the GP IIb-IIIa antagonist integrelin: phase I clinical studies in normal healthy volunteers. (Abstr.). Circulation. 86:((suppl I)):1992;260.
9. Scarborough RM, Rose JW, Hsu MA, Phillips DR, Fried VA, Campbell AM, Nannizzi L, Charo IF. Barbourin: a GP IIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 266:1991;9359-9362.
10. Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips DR, Nannizzi L, Arfsten A, Campbell AM, Charo IF. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem. 268:1993;1066-1073.
11. COR Therapeutics. Data on file.
12. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ, Miller JA, Joseph DM, Sigmon KN, Kitt MM, du Mée CP, Califf RM, Topol EJ. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. Circulation. 91:1995;2151-2157.
13. Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff AM, Tcheng JE, Sigmon KN, Joseph D, Rios G, Trainor K, Rose D, Greenberg CS, Kitt MM, Topol EJ, Califf RM. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol. 76:1995;1222-1227.
14. Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, Anderson HV, Ellis SG, Cohen MD, Spriggs D, Miller M, Kereiakes D, Yakubov S, Kitt MM, Sigmon KN, Califf RM, Krucoff MW, Topol EJ. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. Circulation. 95:1997;846-854.
15. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet. 349:1997;1422-1428.
16. Tcheng JE. Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Am J Cardiol. 80:((suppl 3B)):1997;21-28.
17. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML. Thrombolysis in myocardial infarction (TIMI) trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 11:1988;1-11.